Arrowhead Pharmaceuticals (Nasdaq: ARWR) saw its shares surge 19% to a high of $20.31 pre-market but plunge 15.7% to $16.04 by late morning New York trading, despite announcing a licensing deal that could earn it as much as $3.7 billion.
The company entered into a license and collaboration agreement with Janssen Pharmaceuticals, a part of healthcare giant Johnson & Johnson (NYSE: JNJ), to develop and commercialize ARO-HBV, which has potential as chronic hepatitis B virus (HBV) treatment.
In addition, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen. The transactions have a combined potential value of over $3.7 billion for Arrowhead.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze